• FY26 international revenue grew by 26% to $1.8m
• Achieved an international gross margin of ~68%, 7pp above domestic
• Four international markets contributing with practitioner-led sales
• FY27 priorities include expanding distribution and launching B2B2C portal
• Reviewing additional markets for potential entry

Biome Australia's FY26 International Markets Presentation highlights a 26% increase in international revenue to $1.8 million, with an international gross margin of approximately 68%, seven percentage points above the domestic blend. The company is scaling its practitioner-led model across four international markets, leveraging its clinical evidence and non-discounted approach. Key highlights include the expansion of distribution points to approximately 2,000 and the upcoming launch of a B2B2C portal in H1 FY27. The presentation also outlines FY27 priorities, such as unlocking the Quebec market, expanding Canadian pharmacy chains, and deepening the Irish pharmacy footprint. Additionally, Biome Australia is reviewing additional markets for potential entry, adhering to its disciplined, evidence-led model.

FY26 international revenue: $1.8m; FY26 international gross margin: ~68%

FY27 priorities include Quebec market unlock, Canadian pharmacy chain expansion, UK banner conversion, B2B2C digital health platform launch (H1 FY27), and Ireland pharmacy expansion via Uniphar and new pharmacy banners.